抗生素是药物史中治疗感染的最重要的药物之一。然而，由于抗生素的滥用，导

Antibiotics are one of the most important drugs for treating infections in the history of drugs. However, due to the abuse of antibiotics, drug-resistant bacteria have occurred in clinical practice, and new antibiotics have been ineffective. Bacterial drug resistance is a common health concern of all countries in the world, but the development rate of drug-resistant bacteria is far faster than the research speed of antibacterial drugs, so antibacterial drugs with high activity, low toxicity, and no drug resistance have become research antibacterial drugs The top priority. Antimicrobial peptides (AMPs) are widely-charged hydrophilic and lipophilic natural peptides widely present in multicellular organisms, and are the first line of defense of the immune system against microbial infections. However, antimicrobial peptides have potential in vivo toxicity and are poor Pharmacokinetic properties and other shortcomings, these shortcomings restrict the development. The study found that some small-molecule antimicrobial peptide mimics can overcome the shortcomings of antimicrobial peptides while maintaining their own activity, exhibit good antimicrobial activity, low cytotoxicity and low drug resistance, so we found a breakthrough point.

抗生素是药物史中治疗感染的最重要的药物之一。然而，由于抗生素的滥用，导致耐药菌在临床时有发生，不断有新的抗生素失效。细菌耐药性是世界各国共同关注的健康问题，但是耐药菌的发展速度远远超于抗菌药物的研究速度，因此研发活性高，毒性低，无耐药性的抗菌药物俨然成为研究抗菌药物的重中之重。抗菌肽（Antimicrobial Peptides，AMPs）是多细胞生物体内广泛存在的带正电荷的亲水亲脂天然肽，是免疫系统抵御微生物感染的第一道防线，但抗菌肽存在潜在的体内毒性，较差的药代动力学性质等缺点，这些缺点制约着发展。研究发现一些小分子抗菌肽模拟物在保持其自身活性的前提下又能克服抗菌肽的缺点，展现出良好的抗菌活性，低细胞毒性和低耐药性，让我们寻找到了一个突破点。

Antibiotics are one of the most important drugs in the history of medicine. However, due to the abuse of antibiotics, drug-resistant bacteria occur frequently in clinical practice, and new antibiotics are losing efficacy. Drug resistance of bacteria is a common concern of all countries in the world, but the development speed of drug-resistant bacteria is far faster than the research speed of antibacterial drugs, so the research and development of high activity, low toxicity, non drug resistance of antibacterial drugs has become the top priority. Antimicrobial peptides (AMPS) are a kind of hydrophilic lipophilic natural peptides with positive charge widely existing in multicellular organisms, which are the first defense line of immune system against microbial infection. However, there are some disadvantages of AMPS, such as potential toxicity in vivo and poor pharmacokinetic properties, which restrict the development of amps. It is found that some small molecular antimicrobial peptide analogues can overcome the shortcomings of antimicrobial peptides on the premise of maintaining their own activity, showing good antibacterial activity, low cytotoxicity and low drug resistance, let us find a breakthrough point.<br>